Physician profile
Mark William Clarkson
NPI 1316922412
$1,325.51
in general payments reported to CMS, 2019-2025
15 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $153 · 2021: $18.92 · 2022: $107 · 2023: $311 · 2024: $339 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.11 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $313.15 | 2022-2025 | Nucala |
| Genzyme Corporation | $153.14 | 2021-2024 | |
| Stryker Corporation | $146.83 | 2020-2025 | Audion Et Dilation System |
| Medtronic, INC. | $133.45 | 2024 | Nuvent |
| Acclarent, INC | $129.83 | 2022-2024 | Acclarent Aera |
| Regeneron Healthcare Solutions, INC. | $115.18 | 2019-2023 | Dupixent |
| Integra Lifesciences Corporation | $79.71 | 2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Med-El Corporation | $59.82 | 2019 | |
| Neurent Medical Limited | $57.01 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Amgen INC. | $34.00 | 2025 | |
| Intersect Ent, INC. | $25.36 | 2019 | |
| Alk-Abello, INC | $23.57 | 2020 | |
| Csl Behring | $22.88 | 2025 | Hizentra |
| Davol INC. | $19.18 | 2022 | |
| Aerin Medical INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Clarkson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.